Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HWY0201 is a local anesthetic combination candidate, likely composed of lidocaine and prilocaine, being developed by Kanion Pharmaceutical and Huawe Medicine. It is designed to provide localized pain relief during various gynecological and fertility-related procedures. The drug is currently in Phase 1 clinical development for indications including intrauterine device (IUD) placement and removal, uterine sounding, endometrial sampling, and hysteroscopic or colposcopic interventions. Additionally, it is being evaluated for use in reproductive medicine procedures such as hysterosalpingography, artificial insemination, and embryo transfer. HWY0201 functions by inhibiting voltage-gated sodium channels, thereby blocking the initiation and conduction of nerve impulses to achieve regional anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HWY0201.